Value through Innovation27 July 2016

Clinical Study Results

  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.15
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase IIIa
    Study Title

    Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer

    Study Document Lay summary 1199.15 english
  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.119
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    Phase I dose escalation trial to determine the maximum tolerated dose of BIBF 1120 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with a first, second or third platinum sensitive relapse of advanced epithelial ovarian cancer, fallopian tube or primary peritoneal cancer

    Study Document Lay summary 1199.119 english
  • VARGATEF ® - Carcinoma, Non-Small-Cell Lung
    Clinical Study Number 1199.13
    Study Indication Carcinoma, Non-Small-Cell Lung
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase III
    Study Title

    Multicentre, randomised, double-blind, Phase III trial to investigate the efficacyand safety of oral BIBF 1120 plus standard docetaxel therapy compared toplacebo plus standard docetaxel therapy in patients with stage IIIB/IV orrecurrent non small cell lung cancer after failure of first line chemotherapy(LUME Lung 1)

    Study Document Lay summary 1199.13 english
  • VARGATEF ® - Colorectal Neoplasms
    Clinical Study Number 1199.52
    Study Indication Colorectal Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase III
    Study Title

    A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies

    Study Document Lay summary 1199.52 english
  • VARGATEF ® - Carcinoma, Non-Small-Cell Lung
    Clinical Study Number 1199.238
    Study Indication Carcinoma, Non-Small-Cell Lung
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    A Phase I trial to investigate the effect of nintedanib on the pharmacokinetics of a combination of ethinylestradiol and levonorgestrel in patients with nonsmall cell lung cancer

    Study Document Lay summary 1199.238 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.